102 results
8-K
EX-99.1
CLSD
Clearside Biomedical Inc
7 Aug 19
Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update
4:10pm
to creating and maintaining a commercial infrastructure; it also has the potential to provide access to non-dilutive funding via potential upfront … molecules, and (2) creating
external collaborations with other companies, allowing them access to the SCS so their therapies can be delivered
DEFA14A
CLSD
Clearside Biomedical Inc
26 Apr 24
Additional proxy soliciting materials
4:34pm
materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access … available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights
8-K
EX-99.1
CLSD
Clearside Biomedical Inc
13 Nov 23
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
been granted a new CPT code to help facilitate better access and adoption of the product, and Arctic Vision completed enrollment in their Phase 3 trial … facilitate better access and adoption of the product.
‒Bausch + Lomb presented survey data on positive physician experience using XIPERE in the treatment
DEFA14A
CLSD
Clearside Biomedical Inc
28 Apr 23
Additional proxy soliciting materials
8:42am
. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information … in the shaded box above available when you access the website and follow the instructions. If you want to receive a paper or e-mail copy of the proxy material
8-K
EX-99.1
CLSD
Clearside Biomedical Inc
22 May 19
Regulation FD Disclosure
9:14am
: SCS Microinjector™
Exclusive and Proprietary Access to the Back of the Eye
Differences in Procedures to Reach the Back of the Eye Suprachoroidal … Patient access support PATIENTS Education materials Reimbursement support services PAYERS Proactive education on uveitic macular edema as an unmet need
DEFA14A
g53htpa5
28 Apr 21
Additional proxy soliciting materials
9:23am
DEFA14A
bmx u2mai5zrxvv6
29 Apr 22
Additional proxy soliciting materials
4:35pm
8-K
EX-99.1
p6etf
15 Jun 21
Regulation FD Disclosure
7:16am
8-K
EX-99.1
p0o3zt0rjj5w90nj
20 Nov 19
Other Events
9:00am
8-K
EX-99.1
20py9a
8 Apr 20
Other Events
8:01am
8-K
EX-99.1
0vbp5yej46qlhn
13 Mar 19
Regulation FD Disclosure
7:00am
8-K
EX-99.1
34du0km
8 May 19
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
7:31am
8-K
EX-99.1
rlnf4yr6z26g arvvf
8 Aug 22
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million
4:41pm
8-K
EX-99.1
4ipl8
6 Nov 19
Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
b4vgv
12 Mar 19
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
4:15pm
DRS/A
EX-4
sa88v2m7l3dwanh4
9 Sep 14
Draft registration statement (amended)
12:00am
8-K
EX-99.2
6is01odhy5ad8
15 Jun 21
Regulation FD Disclosure
7:16am
8-K
EX-99.1
ezsqavxj3r0
7 Jan 19
Regulation FD Disclosure
7:01am